semaglutide vs. tirzepatide

Brief comparison between Ozempic/Wegovy (Novo Nordisk's semaglutide) and Mounjaro/Zepbound (Eli Lilly & Co.'s tirzepatide) reported outcomes and adverse events.  
‍
Key differences lie in gastrointestinal (GI) intolerance (nausea, vomiting, delayed gastric emptying) versus issues related to medication use. A significant percentage of serious outcome reports involving hospitalization are frequently co-reported alongside GI adverse events.  
‍
This is an evolving field, marked by relatively recent and staggered approvals, as well as rapidly expanding off-label use. As the metabolic care market matures, at Pharm3r we will continue to deliver key insights into reported outcomes and adverse events.

Download PDF